Media Outreach

Examples of key local, national and trade media placements for current and former clients

Published online August 28th, 2014

Xconomy-logo

Madison Vaccine to be Tested in Combination Prostate Cancer Treatment

by Jeff Engel

Madison Vaccines, a Madison, WI-based startup developing immunotherapies for prostate cancer, will get a chance to see how well its lead vaccine can shrink tumors when teamed up with another drug.

The Phase I trial will be led by Madison Vaccines co-founder Doug McNeel, an oncologist and professor of medicine at the University of Wisconsin-Madison. McNeel and a team of university researchers were awarded a $1.5 million grant to conduct the study. The Movember Foundation is providing the funding through the Movember-Prostate Cancer Foundation Challenge Award program. (read more)

Published online December 11, 2014

cure-logo targeted-oncology onclive-logo

Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial

by Anita T. Shaffer

Gunter-von-Minckwitz

Gunter von Minckwitz, MD, PhD
Photo Courtesy © SABCS/Todd Buchanan 2013

The results are particularly noteworthy because pCR rates were “strongly increased by replacing a key component of the standard neoadjuvant chemotherapy instead of just adding additional agents to it,” Gunter von Minckwitz, MD, PhD, chairman and managing director of GBG, said in a statement.

International multi-lingual coverage too!

la-repubblica

Tumore al seno, in arrivo nuove armi contro le forme più aggressive

ROMA – Sono in arrivo nuove armi contro le forme più aggressive di tumore al seno: innovativi nanofarmaci si sono infatti dimostrati efficaci nel trattamento del tumore del seno in stadio iniziale ad alto rischio, migliorando fino al 9% la risposta terapeutica. “Questa risposta, la cosiddetta risposta patologia completa, è un parametro molto importante”

Translation: New weapons have arrived against the most aggressive form of breast tumors: innovative nano-pharmaceuticals that have demonstrated efficacy in the treatment of early stage breast cancer at high risk, improving by 9% the … pathological complete response “considered to be a very important parameter”

Our team of media specialists develops news making messages that we use to attract media attention, contact our key media contacts and place targeted print articles and broadcast stories

Online Extra – March 6, 2008

businessweek

Take two of these, and go to the gym

by Arlene Weintraub

A new class of drugs could significantly increase the benefits of an overall weight-loss regime. But first, drugmakers have to prove they’re safe

It’s a crisp morning in early February, and Barbara Aukland has arrived at the Scripps Clinic’s Center for Weight Management to get a checkup. She has been participating in a clinical trial for a new weight-loss drug, Contrave, for the past year. The drug was developed by Orexigen Therapeutics (OREX), one of 20-odd companies racing to develop new obesity treatments. Orexigen, it turns out, is based across the street, in a small office park in this neighborhood of northern San Diego.

Contrave is part of the next generation of obesity treatments now making its way through the pharmaceutical industry’s pipeline. About a half-dozen of these new drugs are in critical phase III clinical trials—the final stage of human testing that’s required for product approval from the Food & Drug Administration… (read the whole article here)

Press Release – September 15, 2015

reuters-logo

Madison Vaccines Says Clinical Trial Begins for Its 2nd Prostate Cancer Vaccine, MVI-118, Intended to Delay Disease Progression in Men with Metastatic Disease

Madison Vaccines Says Clinical Trial Begins for Its 2nd Prostate Cancer Vaccine, MVI-118, Intended to Delay Disease Progression in Men with Metastatic Disease

–MVI-118 Represents a Novel Approach to Prostate Cancer Vaccine: Targeting the Androgen Receptor, the Primary Driver of Prostate Cancer Growth and Progression–

Madison Vaccines Incorporated (MVI), today announced dosing has begun in a Phase 1 clinical trial for MVI-118 (pTVG-AR) in men with metastatic prostate cancer who are initiating androgen deprivation therapy (ADT). MVI-118 targets the human androgen receptor, the critical biological target responsible for driving prostate cancer progression and, in many cases, resistance to current therapies. It is being developed to prolong the duration of disease control gained from standard androgen deprivation therapies. The trial will be conducted at the University of Wisconsin – Madison Carbone Cancer Center and two additional Medical Centers.

This is MVI’s second prostate cancer vaccine, along with MVI-816 (pTVG-HP), MVI’s lead vaccine that has demonstrated clinical evidence of safety, immune activation and biological signals (PSA changes) of activity. Both MVI-816 and MVI-118 are plasmid DNA vaccines that differ from other vaccines because they can be rapidly and inexpensively manufactured, can be administered by simple intradermal injection, and are relatively more stable in storage. MVI-118 is intended to provide persistent activation of CD8+ T-cells that target the androgen receptor, a key tumor cell protein that is frequently and highly overexpressed as resistance to ADT emerges. (read more)